[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.234.169. Please contact the publisher to request reinstatement.
Invited Commentary
Dec 10/24, 2012

Moderate Renal Impairment and Risk of Bleeding With Anticoagulation: Comment on “Enoxaparin Outcomes in Patients With Moderate Renal Impairment”

Author Affiliations

Author Affiliation: Department of Medicine, University of California, San Francisco.

Arch Intern Med. 2012;172(22):1718-1720. doi:10.1001/2013.jamainternmed.456

Bleeding is the most feared complication of anticoagulant therapy and, unfortunately, it is not uncommon. The 2011-2012 National Patient Safety Goals mandate efforts to “reduce the likelihood of patient harm associated with the use of anticoagulant therapy.”1 This is a call for coordinated efforts to decrease adverse events related to anticoagulant therapy, with recommendations for improved oversight and evidence-based management of these agents in the inpatient and outpatient settings.

×